



(12) Translation of
European patent specification

(11) NO/EP 3290428 B1

NORWAY

(19) NO

(51) Int Cl.

C07H 19/10 (2006.01)

A61K 31/664 (2006.01)

A61K 31/7072 (2006.01)

A61K 31/716 (2006.01)

A61P 31/00 (2006.01)

A61P 31/14 (2006.01)

C07F 7/18 (2006.01)

C07F 9/22 (2006.01)

C07F 9/24 (2006.01)

C07F 9/6558 (2006.01)

C07F 9/6561 (2006.01)

C07H 19/04 (2006.01)

C07H 19/044 (2006.01)

C07H 19/052 (2006.01)

C07H 19/06 (2006.01)

C07H 19/20 (2006.01)

C07H 19/207 (2006.01)

C07H 19/24 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.01.24
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.10.13
(86)	European Application Nr.	17172585.6
(86)	European Filing Date	2011.03.31
(87)	The European Application's Publication Date	2018.03.07
(30)	Priority	2010.03.31, US, 319513 P, 2010.03.31, US, 319548 P, 2010.05.20, US, 783680
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(62)	Divided application	EP2609923, 2011.03.31
(73)	Proprietor	Gilead Pharmasset LLC, c/o Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
(72)	Inventor	Ross, Bruce S, 155 Del Monte Road, El Granada, CA California 94018, USA Sofia, Michael Joseph, 3066 Antler Drive, Doylestown, PA Pennsylvania 18902, USA Pamulapati, Ganapati Reddy, 1709 Blakesley Drive, San Ramon, CA California 94582, USA Rachakonda, Suguna, 1272 Sharonbrook Drive, Twinsburg, OH Ohio 44087, USA Zhang, Hai-Ren, 6767 Mason Way, San Jose, CA California 95129, USA Chun, Byoung-Kwon, 135 Heritage Street, Robbinsville, NJ New Jersey 08691, USA Wang, Peiyuan, 42 Continental Circle, Totowa, NJ New Jersey 07512, USA
(74)	Agent or Attorney	OSLO PATENTKONTOR AS, Hoffsvæien 1A, 0275 OSLO, Norge
(54)	Title	TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE

(56) References

Cited:

WO-A1-2010/135569


WO-A2-2008/121634

MICHAEL J. SOFIA ET AL: "Discovery of a beta-D-2'-Deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 19, 16 September 2010 (2010-09-16), pages 7202-7218, XP055004442, ISSN: 0022-2623, DOI: 10.1021/jm100863x

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Tablett omfattende krystallinsk (S)-isopropyl-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diookso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksey-4-metyltetrahydrofuran-2-yl)metoksy)(fenoksy)fosforyl)amino)propanoat
- 5 representert ved formel Sp-4:



som har XRPD 2 θ -refleksjoner ($\pm 0,2^\circ$) ved 6,1, 8,2, 10,4, 12,7, 17,2, 17,7, 18,0, 18,8, 19,4, 19,8, 20,1, 20,8, 21,8 og 23,3.

2. Tablett ifølge krav 1 for anvendelse ved behandling av infeksjon med
- 10 hepatitt C-virus.